Patent ID: 9149428
Filing Date: 2015-10-06
Classification: A61K,A61P

Abstract:
1. An intraocular implant comprising a cyclic lipid therapeutic agent, a polymer and a low melting cosolvent, wherein the solubility parameters of the cyclic lipid therapeutic agent, the polymer and the low melting cosolvent are all within about 10 Mpa wherein the low melting cosolvent has a melt temperature of between about 50° C. and about 80° C.; wherein the cyclic lipid therapeutic agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, prostaglandin E1, prostaglandin E2, and mixtures thereof; wherein the polymer is a biodegradable polymer selected from the group consisting of polylactic acid, polyglycolic acid, and polylactide-co-glycolide; wherein the low melting cosolvent is selected from the group consisting of decafluorobutane, poly(hexamethylene adipamide), and polyethylene glycol 3350; and wherein the cyclic lipid agent comprises 20% by weight of the intraocular implant, and wherein the potency of the cyclic lipid therapeutic agent released from the implant is at least about 50% of its maximum potency.